HC Wainwright & Co. Initiates Coverage On Prime Medicine with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and set a price target of $10.
May 20, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Prime Medicine with a Buy rating and set a price target of $10.
The initiation of coverage with a Buy rating and a specific price target of $10 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100